What is ADGM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ADGM?

P/E (TTM) is n/a and 52-week range is $0.08 to $2.02 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ADGM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ADGM?

The company profile lists net income (TTM) near $-32M, EPS (TTM) near $-1.44 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Adagio Medical Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Laguna Hills, California, US, 22.2M shares outstanding, ISIN US00534B1008 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Free AI scores & summaries library

Adagio Medical Holdings Inc

$ADGM

Health Care · Health Care Equipment & Supplies

Run Scenarios

$0.10

-0.10%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Adagio Medical Holdings, Inc. is a medical device company, which engages in the development ablation technologies for the treatment of cardiac arrhythmias. The company is headquartered in Laguna Hills, California and currently employs 41 full-time employees. The company went IPO on 2021-02-26. The firm is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation.

Employees

Website

www.perceptivelife.com/arya4/

IPO

2021-02-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)